- Home
- HTH vs VERA Comparison
HTH vs VERA Comparison
Compare HTH & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTH | VERA |
|---|---|---|
| Founded | 1998 | 2016 |
| Country | United States | United States |
| Employees | N/A | 339 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.5B |
| IPO Year | 2003 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HTH | VERA |
|---|---|---|
| Price | $37.73 | $35.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $37.50 | ★ $81.30 |
| AVG Volume (30 Days) | 267.2K | ★ 909.4K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | ★ 51.72 | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $152,188,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.22 | $472.48 |
| P/E Ratio | $58.77 | ★ N/A |
| Revenue Growth | ★ 15.52 | N/A |
| 52 Week Low | $28.92 | $19.07 |
| 52 Week High | $40.41 | $56.05 |
Technical Indicators
Market Signals| Indicator | HTH | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 56.59 | 46.16 |
| Support Level | $36.34 | $33.43 |
| Resistance Level | $38.73 | $42.77 |
| Average True Range (ATR) | 0.86 | 1.94 |
| MACD | 0.06 | 0.11 |
| Stochastic Oscillator | 77.37 | 38.42 |
Price Performance
Historical ComparisonAbout HTH Hilltop Holdings Inc.
Hilltop Holdings Inc is a Dallas-based financial holding company. The company has three segments: The banking segment includes the operations of the Bank; The broker-dealer segment includes the operations of Securities Holdings,; and the mortgage origination segment is composed of PrimeLending. Majority of revenue is from Broker-dealer Segment.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.